Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78793
Title:
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study.
Authors:
Anderson, Heather; Addington-Hall, J M; Peake, M D; McKendrik, J; Keane, K; Thatcher, Nick
Abstract:
A study was conducted to investigate the feasibility and acceptability of administering single-agent gemcitabine to patients with advanced non-small-cell lung cancer (NSCLC) in their own homes. Gemcitabine is an active agent in NSCLC with a good toxicity profile and lends itself to this type of investigation. A total of 24 patients were studied; as only one patient required gemcitabine to be changed from home administration to hospital administration, domiciliary gemcitabine is feasible. A total of 249 injections of gemcitabine were given, the mean number of courses being 3.5, range 1-6. The gemcitabine was given at 1000 mg m(-2) on days 1, 8 and 15, the courses being repeated every 28 days. All patients received their first course in hospital and in total 147 were given at home and only 14 in hospital on courses 2-6. Furthermore, both the patients and carers reported positively on the use of domiciliary gemcitabine and preferred it over hospital administration. There was no evidence of increasing burden to community services during the domiciliary chemotherapy. Further studies investigating this approach are warranted.
Affiliation:
Department of Medical Oncology, Wythenshawe Hospital, Manchester, UK.
Citation:
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. 2003, 89 (12):2190-6 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
15-Dec-2003
URI:
http://hdl.handle.net/10541/78793
DOI:
10.1038/sj.bjc.6601420
PubMed ID:
14676793
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorAnderson, Heather-
dc.contributor.authorAddington-Hall, J M-
dc.contributor.authorPeake, M D-
dc.contributor.authorMcKendrik, J-
dc.contributor.authorKeane, K-
dc.contributor.authorThatcher, Nick-
dc.date.accessioned2009-08-27T08:16:50Z-
dc.date.available2009-08-27T08:16:50Z-
dc.date.issued2003-12-15-
dc.identifier.citationDomiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study. 2003, 89 (12):2190-6 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid14676793-
dc.identifier.doi10.1038/sj.bjc.6601420-
dc.identifier.urihttp://hdl.handle.net/10541/78793-
dc.description.abstractA study was conducted to investigate the feasibility and acceptability of administering single-agent gemcitabine to patients with advanced non-small-cell lung cancer (NSCLC) in their own homes. Gemcitabine is an active agent in NSCLC with a good toxicity profile and lends itself to this type of investigation. A total of 24 patients were studied; as only one patient required gemcitabine to be changed from home administration to hospital administration, domiciliary gemcitabine is feasible. A total of 249 injections of gemcitabine were given, the mean number of courses being 3.5, range 1-6. The gemcitabine was given at 1000 mg m(-2) on days 1, 8 and 15, the courses being repeated every 28 days. All patients received their first course in hospital and in total 147 were given at home and only 14 in hospital on courses 2-6. Furthermore, both the patients and carers reported positively on the use of domiciliary gemcitabine and preferred it over hospital administration. There was no evidence of increasing burden to community services during the domiciliary chemotherapy. Further studies investigating this approach are warranted.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subject.meshAged-
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshDeoxycytidine-
dc.subject.meshFeasibility Studies-
dc.subject.meshFemale-
dc.subject.meshHome Care Services-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasm Staging-
dc.subject.meshQuality of Life-
dc.subject.meshTreatment Outcome-
dc.titleDomiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Wythenshawe Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.